We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
On January 1, 2012, manufacturers of drugs, biologics, devices and medical supplies covered under Medicare, Medicaid and the Children’s Health Insurance Program must begin tracking payments and other transfers of value made to physicians and teaching hospitals in order to comply with federal requirements known as the federal payment sunshine law (“Sunshine Law”
On February 15, 2011, the United States Food and Drug Administration (FDA) issued a final rule formally "reclassifying" Medical Device Data Systems (MDDSs) from Class III into Class I
On December 14, 2011, the Centers for Medicare & Medicaid Services (CMS) released long-awaited guidance on the implementation of the Federal Sunshine Law (42 U.S.C. 1320a-7h) in the form of a proposed rule
